⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABSI News
Absci Corporation Common Stock
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
globenewswire.com
ABSI
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
globenewswire.com
ABSI
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
globenewswire.com
ABSI
Absci to Participate in Upcoming Investor Conferences
globenewswire.com
ABSI
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
globenewswire.com
ABSI